Trials / Completed
CompletedNCT02253459
Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer
Phase III Clinical Trials of UTD1 Injection Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced and Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 405 (actual)
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether UTD1 Injection in combination with capecitabine is effective in the treatment of advanced metastatic breast cancer using capecitabine as a control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UTD1 Injection plus capecitabine | |
| DRUG | Capecitabine |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2016-09-01
- Completion
- 2018-12-15
- First posted
- 2014-10-01
- Last updated
- 2019-04-09
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02253459. Inclusion in this directory is not an endorsement.